We have previously demonstrated that modulating the activity of DNMT and HDAC proteins in prostate cancer cell lines and ex vivo human prostate tissue induced the expression of cancer testis antigens (CTAs), which have been proposed as targets for tumor vaccine therapies25. This evidence concerns the gene HDAC9 and prostate carcinoma.